Moore Capital Management LP Acquires Shares of 55,000 Bio-Rad Laboratories, Inc. $BIO

Moore Capital Management LP bought a new position in Bio-Rad Laboratories, Inc. (NYSE:BIO) during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 55,000 shares of the medical research company’s stock, valued at approximately $15,421,000. Moore Capital Management LP owned 0.20% of Bio-Rad Laboratories as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in BIO. Quent Capital LLC bought a new position in shares of Bio-Rad Laboratories in the third quarter worth about $25,000. Farther Finance Advisors LLC lifted its holdings in Bio-Rad Laboratories by 52.9% during the 3rd quarter. Farther Finance Advisors LLC now owns 104 shares of the medical research company’s stock valued at $29,000 after buying an additional 36 shares in the last quarter. Geneos Wealth Management Inc. lifted its holdings in Bio-Rad Laboratories by 115.2% during the 2nd quarter. Geneos Wealth Management Inc. now owns 142 shares of the medical research company’s stock valued at $34,000 after buying an additional 76 shares in the last quarter. CWM LLC boosted its position in Bio-Rad Laboratories by 82.0% in the 3rd quarter. CWM LLC now owns 202 shares of the medical research company’s stock valued at $57,000 after buying an additional 91 shares during the period. Finally, UMB Bank n.a. boosted its position in Bio-Rad Laboratories by 24.0% in the 3rd quarter. UMB Bank n.a. now owns 207 shares of the medical research company’s stock valued at $58,000 after buying an additional 40 shares during the period. 65.24% of the stock is owned by hedge funds and other institutional investors.

Bio-Rad Laboratories Trading Down 0.6%

Shares of NYSE BIO opened at $261.17 on Tuesday. Bio-Rad Laboratories, Inc. has a 1-year low of $211.43 and a 1-year high of $343.12. The business has a fifty day moving average price of $290.85 and a 200 day moving average price of $300.06. The stock has a market capitalization of $7.05 billion, a P/E ratio of 9.36 and a beta of 1.18. The company has a debt-to-equity ratio of 0.16, a current ratio of 5.62 and a quick ratio of 4.19.

Bio-Rad Laboratories (NYSE:BIO) last posted its earnings results on Thursday, February 12th. The medical research company reported $2.51 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.57 by ($0.06). The company had revenue of $693.20 million during the quarter, compared to analysts’ expectations of $694.64 million. Bio-Rad Laboratories had a net margin of 29.42% and a return on equity of 3.86%. Bio-Rad Laboratories’s revenue for the quarter was up 3.9% on a year-over-year basis. During the same quarter last year, the firm earned $2.90 EPS. Equities research analysts expect that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have recently commented on BIO shares. Wall Street Zen lowered shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research report on Saturday, February 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of Bio-Rad Laboratories in a research note on Monday, December 29th. Three analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $358.50.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc is a global provider of life science research and clinical diagnostic products. The company operates through two primary business segments: Life Science and Clinical Diagnostics. Within the Life Science segment, Bio-Rad offers instruments, reagents and consumables for protein analysis, cell biology, gene expression and other molecular biology applications. The Clinical Diagnostics segment supplies quality control products, blood-typing reagents and instruments, and molecular diagnostic assays used in blood screening, infectious disease testing and routine clinical laboratories.

Founded in 1952 by David and Alice Schwartz and headquartered in Hercules, California, Bio-Rad has grown its footprint across the Americas, Europe, Asia-Pacific and other regions.